Analysis of information sources in references of the Wikipedia article "Ranbaxy Laboratories" in Malay language version.
The FDA's investigations revealed a pattern of questionable data raising significant questions regarding the reliability of certain applications, and this warrants applying the Application Integrity Policy, said Deborah Autor, director of CDER's Office of Compliance.
The U.S. Food and Drug Administration today issued an import alert under which U.S. officials may detain at the U.S. border drug products manufactured at Ranbaxy Laboratories, Ltd.’s facility in Mohali, India. The firm will remain on the import alert until the company complies with U.S. drug manufacturing requirements, known as current good manufacturing practices (CGMP).
Ranbaxy [..] entered the U.S. generic pharmaceutical market in 1995 introducing its first product under the Ranbaxy Pharmaceuticals Inc. label in January 1998
